SCARB2 and Parkinson disease: This study reveals LIMP‐2 and the LIMP‐2‐derived peptide as an allosteric activator of GCase, potentially opening up new approaches for the development of urgently needed novel therapeutic strategies in order to rescue GCase activity in GD and PD.